Chuntova, P. et al. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 23, 356–375 (2021).
Google Scholar
Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830 (2018).
Google Scholar
Chiocca, E. A., Nakashima, H., Kasai, K., Fernandez, S. A. & Oglesbee, M. Preclinical toxicology of rQNestin34.5v.2: an oncolytic herpes virus with transcriptional regulation of the ICP34.5 neurovirulence gene. Mol. Ther. Methods Clin. Dev. 17, 871–893 (2020).
Google Scholar
Kambara, H., Okano, H., Chiocca, E. A. & Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65, 2832–2839 (2005).
Google Scholar
Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231–1251 (2021).
Google Scholar
Wen, P. Y. & Packer, R. J. The 2021 WHO classification of tumors of the central nervous system: clinical implications. Neuro Oncol. 23, 1215–1217 (2021).
Google Scholar
Vargas Lopez, A. J. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 23, 502–503 (2021).
Google Scholar
Taslimi, S., Ye, V. C., Wen, P. Y. & Zadeh, G. Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma. Neurooncol. Adv. 3, vdab029 (2021).
Google Scholar
Macedo, N., Miller, D. M., Haq, R. & Kaufman, H. L. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer 8, e001486 (2020).
Google Scholar
Martin, N. T. & Bell, J. C. Oncolytic virus combination therapy: killing one bird with two stones. Mol. Ther. 26, 1414–1422 (2018).
Google Scholar
Peruzzi, P. & Chiocca, E. A. Viruses in cancer therapy—from benchwarmers to quarterbacks. Nat. Rev. Clin. Oncol. 15, 657–658 (2018).
Google Scholar
Russell, L. & Peng, K. W. The emerging role of oncolytic virus therapy against cancer. Chin. Clin. Oncol. 7, 16 (2018).
Google Scholar
Totsch, S. K. et al. Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene 38, 6159–6171 (2019).
Google Scholar
Harrington, K. J. et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev. Anticancer Ther. 15, 1389–1403 (2015).
Google Scholar
Christie, J. D. & Chiocca, E. A. Treat and repeat: oncolytic virus therapy for brain cancer. Nat. Med. 28, 1540–1542 (2022).
Google Scholar
Todo, T., Ino, Y., Ohtsu, H., Shibahara, J. & Tanaka, M. A phase I/II study of triple-mutated oncolytic herpes virus G47 in patients with progressive glioblastoma. Nat. Commun. 13, 4119 (2022).
Google Scholar
Todo, T. et al. Intratumoral oncolytic herpes virus G47 for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 1630–1639 (2022).
Google Scholar
Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150–161 (2018).
Google Scholar
Gallego Perez-Larraya, J. et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N. Engl. J. Med. 386, 2471–2481 (2022).
Google Scholar
Friedman, G. K. et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N. Engl. J. Med. 384, 1613–1622 (2021).
Google Scholar
Lang, F. F. et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 36, 1419–1427 (2018).
Google Scholar
Fares, J. et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol. 22, 1103–1114 (2021).
Google Scholar
van Putten, E. H. P. et al. Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies. Clin. Cancer Res. 28, 1572–1585 (2022).
Google Scholar
Kanai, R. et al. Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J. Virol. 86, 4420–4431 (2012).
Google Scholar
Peters, C. et al. Restriction of replication of oncolytic herpes simplex virus with a deletion of γ34.5 in glioblastoma stem-like cells. J. Virol. https://doi.org/10.1128/JVI.00246-18 (2018).
Orvedahl, A. et al. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe 1, 23–35 (2007).
Google Scholar
Aghi, M., Visted, T., Depinho, R. A. & Chiocca, E. A. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 27, 4249–4254 (2008).
Google Scholar
Fyllingen, E. H. et al. Survival of glioblastoma in relation to tumor location: a statistical tumor atlas of a population-based cohort. Acta Neurochir. 163, 1895–1905 (2021).
Google Scholar
Lasocki, A., Gaillard, F., Tacey, M., Drummond, K. & Stuckey, S. Multifocal and multicentric glioblastoma: Improved characterisation with FLAIR imaging and prognostic implications. J. Clin. Neurosci. 31, 92–98 (2016).
Google Scholar
Li, Y. et al. A systematic review of multifocal and multicentric glioblastoma. J. Clin. Neurosci. 83, 71–76 (2021).
Google Scholar
Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015).
Google Scholar
Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
Google Scholar
Ohgaki, H. & Kleihues, P. Epidemiology and etiology of gliomas. Acta Neuropathol. 109, 93–108 (2005).
Google Scholar
Keles, G. E., Lamborn, K. R., Chang, S. M., Prados, M. D. & Berger, M. S. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J. Neurosurg. 100, 41–46 (2004).
Google Scholar
Huang, Y. et al. Receptors and ligands for herpes simplex viruses: novel insights for drug targeting. Drug Discov. Today 27, 185–195 (2022).
Google Scholar
Meier, S. L., Satpathy, A. T. & Wells, D. K. Bystander T cells in cancer immunology and therapy. Nat. Cancer 3, 143–155 (2022).
Google Scholar
Massa, C. et al. Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients. Oncotarget 8, 21212–21228 (2017).
Google Scholar
Werner, L. et al. Alterations in T and B cell receptor repertoires patterns in patients with IL10 signaling defects and history of infantile-onset IBD. Front. Immunol. 11, 109 (2020).
Google Scholar
Tickotsky, N., Sagiv, T., Prilusky, J., Shifrut, E. & Friedman, N. McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences. Bioinformatics 33, 2924–2929 (2017).
Google Scholar
Luoma, A. M. et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell 185, 2918–2935 (2022).
Google Scholar
Held, K. et al. αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell-related features. Neurol. Neuroimmunol. Neuroinflamm. 2, e107 (2015).
Google Scholar
Savola, P. et al. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nat. Commun. 8, 15869 (2017).
Google Scholar
Tomaszewski, W., Sanchez-Perez, L., Gajewski, T. F. & Sampson, J. H. Brain tumor microenvironment and host state: implications for immunotherapy. Clin. Cancer Res. 25, 4202–4210 (2019).
Google Scholar
Guerra, G. et al. Antibodies to varicella-zoster virus and three other herpesviruses and survival in adults with glioma. Neuro Oncol. https://doi.org/10.1093/neuonc/noac283 (2023).
Harrow, S. et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 11, 1648–1658 (2004).
Google Scholar
Markert, J. M. et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 17, 199–207 (2009).
Google Scholar
Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119 (2017).
Google Scholar
Alayo, Q. A. et al. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. Sci. Rep. 10, 5095 (2020).
Google Scholar
Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515–525 (2021).
Google Scholar